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ABSTRACT 
Imipenem-resistant Acinetobacter baumannii (A. baumannii) (IRAB) has emerged as a challenging nosocomial pathogen particularly in 
intensive care units (ICUs). Studying the risk factors associated with IRAB infection is of paramount importance for appropriate 
control of IRAB spread. The aim of this study was to assess the incidence rate and possible risk factors associated with nosocomial 
IRAB infections in ICUs. A prospective cohort study was carried out in surgical and emergency ICUs of a tertiary care hospital in 
Egypt. All patients who developed nosocomial A. baumannii  infection from the start of January 2014 to the end of December 2015 
were included. Isolates were identified as A. baumannii using API 20NE and E-test was used to define IRAB. Out of 146 A. baumannii 
isolates, 11 were found to be IRAB (7.5% incidence rate), of them 72.7% (8/11) were found to be multidrug resistant (MDR).  
Univariate analysis demonstrated that hospital stay before ICU admission [Relative risk (RR) 3.51, 95% confidence interval (CI) 1.0-
12.7, P= 0.04)], longer ICU stay (P= 0.005), exposure to emergent surgery (RR 17.5, CI 7.39-41.4, P= 0.000), the presence of central 
venous catheter (RR 3.26, CI 1.0-10.6, P= 0.04) and previous carbapenem use (RR 4.05, CI 1.12-14.6, P =0.02) were significant risk 
factors for IRAB infection. In conclusion, a relatively high IRAB incidence was recorded in ICUs of our hospital. Hospital stay before 
ICU admission, longer ICU stay, exposure to emergent surgery, the presence of central venous catheter and previous carbapenem 
use were significant risk factors for IRAB infection. Rationale use of carbapenems in ICUs should be considered.  
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RESUME 
Acinebacter Baumannii (A. baumannii) résistant à l’imipenème (IRAB) a émergé comme une pathogène difficile en particulier 
dans les unités de soins intensifs (USI). L’étude des facteurs de risque associe à l’infection IRAB est d’une importance capitale 
pour le contrôle de la propagation de l’IRAB. Le but de cette étude était d’évaluer le taux d’incidence et les facteurs de risque 
possibles associesà des infections nosocomiales d’IRAB dans les USI. Une étude de cohorte prospective a été menée dans une 
USI chirurgicale et d’urgence d’un hôpital de soins tertiaire en Egypte. Tous les patients qui ont développé l’infection A. 
baumannii depuis le début de janvier 2014 jusqu’à la fin de décembre 2015 ont été inclus. Les isolats ont été identifiés comme A. 
baumannii en utilisant API 20NE et E – test a été utilisé pour définir l’IRAB. Sur 146 isolats d’A. baumannii, 11 ont été trouvés 
d’être IRAB (7,5% taux d’incidence), d’entre eux, 72,7% (8/11) ont été trouvés multi résistantes (MDR). Analyse univariée a 
montré que l’hospitalisation avant l’admission USI [Risque relative (RR)3,51, 95% intervalle de confiance (CI) 1,0-12,7, P=0.04)], 
long séjour à USI (P=0.0005), l’exposition à la chirurgie d’urgence (RR 17,5    CI 7,39-41.4,   P= 0,000), la présence d’un cathéter 
veineux central (RR 3,26,   CI 1,0-10,6      P=0.04) et l’usage de carbapenemprécédente (RR  4,05      CI  1,12-14.6     P=0,02) étaient 
des facteurs de risque importants d’infection IRAB. En conclusion, un incident relativement élevé d’IRAB a été enregistréà USI 
de notre hôpital. Séjour à l’hôpital avant l’admission à l’unité de soins intensifs, long séjour à USI, l’exposition à la chirurgie 
d’urgence, la présence d’un cathéter veineux central, et l’utilisation de carbapenemprécédenteétaient des facteurs de risque 
important pour l’infection d’IRAB.  L’utilisation rationnelle des carbapanemes en USI devrait êtreconsidéré. 
Mots clés : Résistant àImipenème, Acinebacterbaumanniiunité des soins intensifs. 
 
INTRODUCTION                                                           
Acinetobacter spp., in particular Acinetobacter 
baumannii (A. baumannii), are opportunistic pathogens 
frequently involved in nosocomial infections. These  
 
occur mostly in intensivecare units (ICUs). These 
infections can range from urinary tract infections 
(UTI) to pneumonia and septicemia (1).  The ability of 
these bacteria to survive for long periods on dry 
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inanimate surfaces as well as their ability to persist on 
human skin can potentiate the risk of cross-
contamination in hospital settings resulting in 
endemic and/or epidemic outbreaks of infection (2,3). 
This could result in secondary morbidity particularly 
in patients with serious underlying diseases, but 
whether these infections have an attributable 
mortality, is controversial (4). 
Isolates of A. baumannii are well known for their 
antibiotic resistance and multidrug-resistant (MDR) 
strainshave emerged globally (5). Carbapenems are 
often considered the antibiotics of last choice for 
treating infections caused by A. baumannii. 
Unfortunately, carbapenem-resistant A. 
baumannii(CRAB) has become a worldwide issue (6). 
Moreover, these isolates are often MDR, which 
constitutes a great challenge to the treating physician, 
who finds himself facing an untreatable organism.  
In spite of the extreme difficulty recorded in 
controlling CRAB in hospital settings, successful trials 
have been reported previously (7,8). This indicates 
that the strict implementation of infection control 
measures, rationale use of antimicrobials according to 
a sound policy, regular antimicrobial resistance 
surveillances, as well as risk factor assessment, may 
help control or contain the threat of this challenging 
organism.  
This work aimed to assess the incidence and possible 
risk factors associated with nosocomial infections 
caused by imipenem-resistant A. baumannii (IRAB) in 
ICUs of a tertiary care hospital in Egypt. 
MATERIALS AND METHODS 
Study population and Case definition  
A prospective cohort study was conducted in the 
emergency and the surgical ICUs of Zagazig 
University Hospitals, a tertiary care hospital in the 
eastern governorate of Egypt. Patients who had A. 
baumannii infections from the start of January 2014 to 
the end of December 2015 were included in the study. 
Only the initial A. baumannii isolate from each patient 
was included. The clinical significance (colonization 
or infection) of each A. baumannii isolate was assessed 
according to Centre for Disease Control (CDC) criteria 
(9,10). For patients with an indwelling bladder 
catheter, UTI was diagnosed with detection of 
pyuria(10 leukocytes/mm3), growth of ≥105 CFU/ml 
bacteria (with no more than two species) in urine 
culture, and the presence of clinical signs of infection 
(fever 38˚C, leukocytosis, abnormal macroscopic 
appearance of urine, presence of urinary nitrites). In 
mechanically ventilated patients, pneumonia was 
diagnosed by the presence of a new or progressive 
infiltrate in chest X-ray with the presence of purulent 
endotracheal aspirates, supported by a growth of ≥105 
CFU/ml bacteria in a quantitative culture of deep 
endotracheal aspirate. For non-ventilated patients, the 
diagnosis of pneumonia was made when patients had 
a compatible chest X-ray and purulent sputum, with 
Gram stain and sputum culture yielding a pathogenic 
microorganism. Surgical site infection (SSI) was 
diagnosed by the presence of purulent discharge and 
presence of suggestive clinical signs (incision site 
pain, tenderness, localized swelling, redness or heat, 
spontaneous opening of the incision) supported by 
microbiologic results of specimen analysis. Diagnosis 
of sepsis was made by the presence of positive blood 
cultures and sepsis criteria. Patients colonized with A. 
baumannii as well as patients from whom A. baumannii 
isolates had been recovered within 48 h of admission 
to ICU were excluded. Data were recorded on 
individual forms for each patient. The form included 
age, gender, diagnosis, length of hospital stay before 
ICU admission (if any), length of ICU stay, 
comorbidity (diabetes mellitus, renal insufficiency, 
dialysis, hepatic failure, malignancy, 
immunosuppression, neutropenia, chronic lung 
disease, malnutrition and anoxic encephalopathy), 
emergent surgical operations, ventilator support, 
physical examination findings, hematological and 
biochemical test results, antibiotics given to the 
patient, culture and antimicrobial susceptibility test 
results, and time between admission to ICU and 
isolation of the first positive A. baumannii culture. 
Carbapenem uptake during 14 days (for at least 24 h) 
prior to isolation of the A. baumannii was considered 
(11).For all included patients, written or verbal 
informed consent was obtained from the patients 
themselves, or their guardians. Patients were assigned 
as IRAB cases if they had imipenem-resistant A. 
baumannii infections and as ISAB cases if they had 
imipenem-sensitive A. baumannii infections.  
Microbiologic examination 
This was carried out at the Microbiology and 
Immunology Department, Faculty of Medicine, 
Zagazig University.Identification of isolates as A. 
baumannii was performed using API 20NE (Bio-
Mérieux, Marcy L´Etoile, France). The minimum 
inhibitory concentration (MIC) of the identified 
isolates for imipenem was determined using E-test 
(Bio-Mérieux, Marcy L´Etoile, France) according to 
the manufacturerʼs instructions. Isolateswereassigned 
as IRAB if theyhad MIC values ≥ 8 µg/ml, while those 
with MIC values <8 µg/ml were assigned as ISAB 
(12). In addition, all identified isolates were tested 
against the following antibiotics; amikacin, 
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gentamicin, aztreonam, cefipime, ceftazidime, 
ciprofloxacin, levofloxacin, piperacillin—tazobactam, 
trimethoprim—sulfamethoxazole, tigecycline and 
colistin by disc diffusion method. All discs were 
supplied from Bioanalyse 
(TibbiMalzemelerSanayiveTicaret Ltd. Sti., Turkey) 
except tigecycline was from Oxoid, England. Isolates 
were identified as being MDR if resistance to at least 
one agent in more than three antimicrobial categories 
was detected (13). 
Statistical analysis 
Potential risk factors were analyzed by univariate 
analysis. Independent Student’s t-test, Chi-square test 
and Fisher’s exact tests were used when appropriate 
to compare proportions. A P value of <0.05 was 
considered statistically significant.  
RESULTS 
One hundred and forty-six non-repeated A. baumannii 
were isolated from an equal number of patients 
during the study period. IRAB was isolated from 11 
(7.5%) patients while 135 isolates (92.5%) were ISAB. 
The isolation frequency of both IRAB and ISAB from 
different nosocomial infections is presented in Table 
1. Lower respiratory tract infection (LRTI) and SSI 
represented the main infections from which IRAB 
were isolated (36.4% isolation frequency for each), 
followed by UTI (18.2%) and then blood stream 
infection (9.1 %). No significant difference was found 
between IRAB and ISAB regarding the type of 
infection (Table 1). 
 
TABLE 1: ISOLATION FREQUENCY OF IMIPENEM-RESISTANT A. BAUMANNII (IRAB) AND IMIPENEM-SENSITIVE A. 
BAUMANNII (ISAB) FROM DIFFERENT NOSOCOMIAL INFECTIONS 
Type of infection IRAB (n = 11)  
No. (%) 
ISAB (n = 135)  
No. (%) 
Total (n = 146)  
No. (%) 
P 
Surgical site infection (SSI) 4 (36.4) 45 (33.3) 49 (33.56) 0.8 
Urinary tract infection (UTI) 2 (18.2) 41 (30.4) 43 (29.5) 0.4 
Lower respiratory tract infection 
(LRTI) 
4 (36.4) 29 (21.5) 33 (22.6) 0.3 
Blood stream infection 1 (9.1) 20 (14.8) 21 (14.4) 0.6 
 
The susceptibility profiles of IRAB and ISAB isolates 
to the tested antimicrobials in disc diffusion method 
are presented in Table 2. All IRAB isolates were 
susceptible to colistin, followed by tigecycline 
(81.8%), while they were all resistant to cefepime.  
Multidrug resistance was detected in 72.7% of IRAB 
isolates (8/11). 
Univariate analysis of different factors associated 
with IRAB infection (Table 3) demonstrated that five 





These included; hospital stay before ICU admission 
(RR 3.51, CI 1.0-12.7, P= 0.04), longer ICU stay 
(21.5±6.1 day with IRAB, compared to 16.1±5.6 day 
with ISAB, P= 0.005), exposure to emergent surgery 
(RR 17.5, CI 7.39-41.4, P= 0.000), the presence of 
central venous catheter (RR 3.26, CI 1.0-10.6, P= 0.04) 




TABLE 2: ANTIMICROBIAL SUSCEPTIBILITY RATES OF IMIPENEM-RESISTANT A. BAUMANNII (IRAB) AND 
IMIPENEM-SENSITIVE A. BAUMANNII (ISAB) ISOLATES TO THE TESTED ANTIMICROBIALS IN DISC DIFFUSION 
TEST 





Amikacin 2 (18.2) 72 (53.3) 0.24 
Gentamycin 1 (9.09) 64 (47.4) 0.01* 
Aztreonam 2 (18.2) 78 (57.8) 0.01* 
Cefipime 0 (0.0) 17 (12.6) ------- 
Ceftazidime 4 (36.4) 87 (64.4) 0.06 
Ciprofloxacin  3 (27.3) 92 (68.1) 0.006** 
Levofloxacin  6 (54.54) 113 (83.7) 0.16 
Piperacillin-tazobactam 5 (45.5) 97 (71.85) 0.06 
Trimethoprim-Sulfamethoxazole 2 (18.2) 77 (57) 0.12 
Tigecycline 9 (81.8) 127 (94.1) 0.12 
Colistin 11 (100) 135 (100) ------- 
*significant, **highly significant 
TABLE 3: UNIVARIATE ANALYSIS OF RISK FACTORS FOR IMIPENEM-RESISTANT A.BAUMANNII (IRAB) INFECTIONS 
Risk factors IRAB  
(n = 11)                                                    
  ISAB                                    
 (n = 135)  
RR (95% CI) P 
  







5 (6.9)                                       
 







Presence of comorbidity 
Yes (n=59) 

























Mean length of ICU stay in days  ± 
SD 
















5 (5.0)                                96 (95.0) 




























































































































RR; Relative risk, CI; Confidence interval,*significant, **highly significant 
 
DISCUSSION                                                                                                                                                                                                     
In this work,146 A.baumannii were isolated from an 
equal number of patients during the study period. 
IRAB was isolated from 11 patients accounting for 
7.5% isolation frequency. In USA and Canada, the 
incidence of imipenem resistance in Acinetobacter 
spp. ranged from 6-8%. Higher levels were recorded 
in Latin America and Europe (10% and 16%, 
respectively) (14,15,16). In Asian countries, the 
prevalence ranged from 2% to 26% (17,18). Marked 
increase in CRAB incidence was reported in a 
previous study from South Africa (19).Variable
results were reported from Arabian countries, 
where the incidence of CRAB ranged from 5.4% in 
Kingdom Saudi Arabia (20) to 37.2% in Kuwait (21) 
to as high as 58% in Manama (22). In a previous 
Egyptian study, a very high incidence was recorded 
in an ICU of a university hospital in Upper Egypt 
(71.4%) (23). These discrepant results may be 
contributed to the different study designs where 
one center evaluation was performed in some 
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studies (23), whereas, other studies were nation-
wide (18). 
In our study, the highest isolation frequency of 
IRAB was from LRTI and SSI (36.4% each), followed 
by UTI (18.2%) and then blood stream infection 
(9.1%). A number of previous studies have reported 
LRTI as the main infection yielding IRAB 
(11,18,19,24). A similar finding was also reported 
previously in Egypt (23). This was not unexpected, 
as previous studies demonstrated that as much as 
two-thirds of hospitalized patients have their 
respiratory tract colonized with A. baumannii (25) 
and that infection by MDR A. baumannii is strongly 
correlated to this initial colonization (26), 
particularly when excessive manipulations are 
encountered as in ICU environment. 
Among the obtained IRAB isolates, 72.7% were 
found to be MDR being resistant to three or more 
different classes of antimicrobials. This is supported 
by a previous study where most of the examined 
CRAB isolates were found to be resistant to all 
tested antimicrobials (27). On the other hand, all 
IRAB isolates were found susceptible to colistin and 
81.8% were susceptible to tigecycline. This comes in 
accordance with what was reported in South Africa 
concerning the susceptibility pattern of CRAB (19). 
Accumulating evidence suggested that A. baumannii 
isolates are difficult to eradicate in hospital settings 
as they rapidly adapt to the hospital environment 
and become endemic with a remarkable ability to 
contaminate hospital equipment and to be 
transmitted via contact and even airborne methods. 
This constitutes a great threat to patients as well as 
to their physicians particularly with mostly an 
untreatable organism such as IRAB (28).  This 
makes the study of the factors that could be 
associated with the acquisition of such an organism 
of paramount importance as it could help control its 
spread. 
Previous studies had assigned different risk factors 
to be significantly associated with IRAB acquisition. 
These included; prolonged hospital stay, prolonged 
ICU stay, exposure to and duration of different 
invasive procedures, exposure to emergent surgical 
procedure, the presence in a unit accommodating 
patients infected with IRAB and previous exposure 
to broad-spectrum antimicrobials particularly 
carbapenems (11,18,24). Our study revealed that 
longer duration of ICU stay (21.5±6.1 with IRAB 
compared to 16.1±5.6 with ISAB infection, P=0.005), 
hospital stay before ICU admission (P=0.04), 
exposure to emergent surgery (P=0.000) and 
exposure to CVC (P= 0.04) were significantly 
associated with IRAB acquisition. Our results are 
supported by previous studies that demonstrated 
the same results (11,29,30). Prior exposure to 
antimicrobials has been recognized as being, by far, 
the most important risk factor for developing of 
multi-drug resistance in A. baumannii (31). This was 
evident with IRAB where exposure to broad-
spectrum antibiotics particularly third generation 
cephalosporins (32), fluoroquinolones (33) and 
carbapenems (11) were all significant risk factors for 
IRAB acquisition. Our result comes to confirm these 
observations where previous carbapenem use was 
significantly associated with IRAB infection 
(P=0.02). This highlights the importance of 
implementing strict antimicrobial policies in health 
care facilities. Further studies that assess the level of 
hygiene and the compliance to infection control 
measures as other risk factors are warranted. 
CONCLUSION                                                                                                                                                                  
In conclusion, the spread of antibiotic resistance 
among clinically important Gram-negative bacilli 
seems to be an unstoppable problem. This study 
demonstrated that the incidence of IRAB in ICUs of 
our hospital is relatively high. Longer ICU stay, 
hospital stay prior to ICU admission, usage of CVC, 
exposure to emergent surgery and prior use of 
carbapenems were all significant risk factors for 
IRAB infection. Restricted use of carbapenems in the 
ICUs of our hospital should be considered.  
Implementation of infection control measures may 
help to control the danger of this challenging 
organism. 
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